Ani Pharmaceuticals (ANIP) Intangibles (2012 - 2026)
Ani Pharmaceuticals (ANIP) posted Intangibles of $467.2 million for Q1 2026, down 2.58% sequentially from $479.5 million in Q4 2025, and down 13.25% YoY from $538.5 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Intangibles (2012 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Intangibles for 15 years, with the latest figure at $467.2 million in Q1 2026.
- Quarterly Intangibles fell 13.25% year-over-year to $467.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $467.2 million (down 13.25% YoY) and the FY2025 annual result came in at $479.5 million, down 11.5% from the prior year.
- Intangibles retreated to $467.2 million in Q1 2026 per ANIP's latest filing, from $479.5 million in the prior quarter.
- Over five years, Intangibles peaked at $569.8 million in Q3 2024 and troughed at $4.3 million in Q2 2023.
- A 5-year average of $307.7 million and a median of $264.2 million in 2022 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2024: Intangibles tumbled 98.41% in 2023, then soared 4157.63% in 2024.
- Over 5 years, Intangibles stood at $251.6 million in 2022, then fell by 16.94% to $209.0 million in 2023, then soared by 159.24% to $541.8 million in 2024, then retreated by 11.5% to $479.5 million in 2025, then slipped by 2.58% to $467.2 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $467.2 million, $479.5 million, and $499.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 3.45 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 918.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 21.28 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 13.68 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 2.23 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 3.20 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 1.12 Bn |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.28 Bn | 165.89 Mn | 449.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 449.86 Mn |
| Mar 31, 2026 | 467.16 Mn |
| Dec 31, 2025 | 479.53 Mn |
| Sep 30, 2025 | 499.82 Mn |
| Jun 30, 2025 | 15.80 Mn |
| Mar 31, 2025 | 538.50 Mn |
| Dec 31, 2024 | 541.83 Mn |
| Sep 30, 2024 | 569.83 Mn |
| Jun 30, 2024 | 183.08 Mn |
| Mar 31, 2024 | 196.04 Mn |
| Dec 31, 2023 | 209.01 Mn |
| Sep 30, 2023 | 219.83 Mn |
| Jun 30, 2023 | 4.30 Mn |
| Mar 31, 2023 | 238.79 Mn |
| Dec 31, 2022 | 251.64 Mn |
| Sep 30, 2022 | 264.24 Mn |
| Jun 30, 2022 | 269.59 Mn |
| Mar 31, 2022 | 281.57 Mn |
| Dec 31, 2021 | 294.12 Mn |
| Sep 30, 2021 | 170.14 Mn |